Literature DB >> 2709733

[Classification and importance of cystoid macular edema in pseudophakia].

W Behrens-Baumann1, C D Quentin, B Eckhardt, M Vogel.   

Abstract

In a prospective study the authors attempted to establish the incidence of cystoid macular edema (CME) in uncomplicated intracapsular cataract extraction with implantation of Choyce Mark IX lenses. Fluorescein angiography was performed after eight days, six weeks, six months, and at least one year post-operatively. Any edema found was classified as Grade I to III. Grade III CME was demonstrated in 4% of the cases studied after six weeks, though not after six months or one year, respectively. After one year, Grade II was found in 2% and Grade I in 15%, respectively. However, visual function was not impaired. At no time was there any correlation between the severity of the macular edema and visual acuity: all combinations are possible. Grade III CME evidently only impairs visual function if it persists for a prolonged period of time. Hyperfluorescence in the late phase of the angiogram permits the breakdown of the blood-aqueous barrier to be estimated semi-quantitatively.

Entities:  

Mesh:

Year:  1989        PMID: 2709733     DOI: 10.1055/s-2008-1046329

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  3 in total

Review 1.  The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery.

Authors:  A J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Cystoid macular edema in anterior chamber lens implantation following posterior capsule rupture.

Authors:  G Nikica; H P Ljerka; P Jelena; K Metez-Soldo; B Mladen
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 3.  Ocular diclofenac. A review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions.

Authors:  K L Goa; P Chrisp
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.